EPKINLY delivered an ORR of 61%, with 38% of patients achieving a deep response of CR1
- The median follow-up for DOR was 9.8 months (range: 0-17.3 months)
- mDOCR* was NR (n=56/148; 95% CI, 14.3 mo-NR)2
- Complete responses were achieved as late as 10.2 months2
- The median follow-up for DOCR was 9.7 months (range: 8.3-12.1 months)2
- The efficacy of EPKINLY was evaluated in EPCORE™ NHL-1, an open-label, multicohort, multicenter, single-arm trial in 148 patients with R/R DLBCL after 2 or more lines of systemic therapy1
Manageable adverse reactions1
- EPKINLY can cause serious side effects, including CRS, ICANS, infections, cytopenias, and embryo-fetal toxicity
- Most common ARs (≥20%) were CRS, fatigue, musculoskeletal pain, injection site reactions, pyrexia, abdominal pain, nausea, and diarrhea
- CRS was primarily low grade, predictable, and manageable, with grade 3 (2.5% of patients) and no grade 4 events
- 3.8% discontinued due to ARs; 34% experienced dosage interruptions
Please see more Important Safety Information.
An off-the-shelf subcutaneous
bispecific antibody for DLBCL1
- Enables rapid treatment initiation at the moment of relapse3
- Prior to starting EPKINLY, provide Pneumocystis jirovecii pneumonia prophylaxis and consider initiating prophylaxis against herpes virus to prevent herpes zoster reactivation
*Based on Kaplan-Meier estimate.
†Efficacy results determined by Lugano criteria (2014) as assessed by Independent Review Committee (IRC).
3L=third line; AR=adverse reaction; CI=confidence interval; CR=complete response; CRS=cytokine release syndrome; DLBCL=diffuse large B-cell lymphoma; DOR=duration of response; ICANS=immune effector cell-associated neurotoxicity syndrome; mDOCR=median duration of complete response; mDOR=median duration of response; NOS=not otherwise specified; NR=not reached; ORR=overall response rate; PR=partial response; R/R=relapsed/refractory.
